Yayın: Pharmacokinetics of intravenous and intramuscular danofloxacin in red-eared slider turtles (Trachemys scripta elegans).
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Corum, Duygu Durna | |
| dc.contributor.author | Altan, Feray | |
| dc.contributor.author | Er, Ayse | |
| dc.contributor.author | Cetin, Gul | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-04T12:25:23Z | |
| dc.date.issued | 2018-11-17 | |
| dc.description.abstract | This study aimed to investigate the pharmacokinetics of danofloxacin in red-eared slider turtle (Trachemys scripta elegans) following a single intravenous (IV) and intramuscular (IM) administrations of 6 mg/kg, using a two-way crossover study with 30-day washout period. Eight clinically healthy red-eared slider turtle weighing 410-600 g (mean 490 g) were used for the study. Danofloxacin concentrations were measured using the reversed-phase high-performance liquid chromatography. The plasma concentration-time data were evaluated by a non-compartmental method. After IV administration, the elimination half-life (t1/2 ʎ z), mean residence time (MRT0-∞), area under the concentration-time curve (AUC0-∞), volume of distribution at steady state and total body clearance in plasma were 24.17 hr, 30.64 hr, 143.31 hr·μg/ml, 1.29 l/kg and 0.04 l/hr/kg, respectively. Following IM administration, t1/2ʎz, MRT0-∞AUC0-∞,peak concentration (Cmax), time to reach Cmax, and bioavailability in plasma were 32.00 hr, 41.15 hr, 198.23 hr·μg/ml, 8.75 μg/ml, 1.5 hr and 139.89%, respectively. Danofloxacin has clinically superior pharmacokinetic properties, including the complete IM absorption, slow elimination and wide volume of distribution in redeared slider turtles. However, further pharmacokinetics/pharmacodynamics studies are necessary for the treatment of diseases caused by susceptible bacteria with known minimum inhibitory concentration values in red-eared slider turtles. | |
| dc.description.abstract | PMID:30853667 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/30853667 | |
| dc.description.uri | http://dx.doi.org/10.1292/jvms.18-0609 | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/b53c9189-9aff-4c1d-86de-e7d5beadc9e8/oai | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/b3c123e9-49b8-446a-9552-49d767b620cf/oai | |
| dc.description.uri | https://www.jstage.jst.go.jp/article/jvms/81/5/81_18-0609/_article | |
| dc.description.uri | https://hdl.handle.net/11468/7582 | |
| dc.description.uri | https://doi.org/10.1292/jvms.18-0609 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/38083 | |
| dc.identifier.issn | 1347-7439 | |
| dc.identifier.openaire | pmid_dedup__::b9f15c4a949a1a751eec64422a8cbcf9 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/37036 | |
| dc.identifier.volume | 81 | |
| dc.language.iso | eng | |
| dc.publisher | The Japanese Society of Veterinary Science | |
| dc.relation.ispartof | The Journal of veterinary medical science | |
| dc.rights | OPEN | |
| dc.subject | Pharmacology | |
| dc.subject | Cross-Over Studies | |
| dc.subject | Bioavailability | |
| dc.subject | Red-eared slider turtles | |
| dc.subject | Biological Availability | |
| dc.subject | Danofloxacin | |
| dc.subject | Injections, Intramuscular | |
| dc.subject | Turtles | |
| dc.subject | Anti-Infective Agents | |
| dc.subject | red-eared slider turtles | |
| dc.subject | Injections, Intravenous | |
| dc.subject | danofloxacin | |
| dc.subject | Animals | |
| dc.subject | Pharmacokinetics | |
| dc.subject | bioavailability | |
| dc.subject | pharmacokinetics | |
| dc.subject | Fluoroquinolones | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics of intravenous and intramuscular danofloxacin in red-eared slider turtles (Trachemys scripta elegans). | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.import.source | OpenAire |
